Somatotropin Deficiency Market to Witness Huge Growth During the Forecast Period Owing to the Development of the Long-acting Growth Hormone

Somatotropin Deficiency Market to Witness Huge Growth During the Forecast Period Owing to the Development of the Long-acting Growth Hormone

“Delveinsight Business Research LLP”
DelveInsight’s “Somatotropin Deficiency Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Somatotropin Deficiency Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Somatotropin is a growth hormone produced by the anterior pituitary. It acts by stimulating the release of somatomedins that mediate anabolic and mitogenic action of growth hormone. Somatotropin is controlled by growth hormone-releasing hormone, which stimulates the pituitary to release growth hormone, and somatostatin, which inhibits that release.

Congenital GHD is caused by genetic mutations or brain deformities or associated with midline facial defects such as a cleft palate or single central incisor. Genetic defects such as GHD IA, GHD IB, GHD IIB, III, classic genetic disorder, X-linked genetic disorders, and dominant and recessive genetic disorders are associated with GHD.

Get FREE sample copy at:

The Somatotropin Deficiency Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Somatotropin Deficiency market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Somatotropin Deficiency treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Somatotropin Deficiency Market

Somatotropin Deficiency Market Key Facts

  • A study conducted by Mulder et al. titled “Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: A systematic review” shows that the prevalence of radiation-induced GHD ranges from 29.0% to 39.1%, with a pooled prevalence of 35.6%.

  • As per the study conducted by Sassolas et al. titled “GH deficiency in adults: an epidemiological approach,” the prevalence of adult-onset GHD was 4.6/100,000.

  • As per the study conducted by Lindsay et al. titled “Utah Growth Study: growth standards and the prevalence of growth hormone deficiency,” the prevalence of childhood-onset GHD was 40.6/100,000 in males and 16.1/100,000 in females.

  • According to the study by Lindsay et al., the prevalence of childhood-onset GHD is higher in males than females.

  • A study conducted by Leonhardt et al. titled “Low Prevalence of Isolated Growth Hormone Deficiency in Patients After Brain Injury: Results From a Phase II Pilot Study,” shows that the prevalence of GHD in brain injury patients was 12%.

Key Benefits of Somatotropin Deficiency Market Report

  • Somatotropin Deficiency market report provides an in-depth analysis of Somatotropin Deficiency Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Somatotropin Deficiency Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Somatotropin Deficiency current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Somatotropin Deficiency market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Somatotropin Deficiency Market

The Somatotropin Deficiency market size is expected to increase during the forecast period owing to the R&D activity of the pharma companies and the development of the long-acting growth hormone. The approval of these phase III long-acting GH will surely increase patient compliance.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Somatotropin Deficiency market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Somatotropin Deficiency market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

Somatotropin Deficiency Treatment Market

The most common treatment for somatotropin deficiency in both children and adults is growth hormone replacement therapy. Other treatment options include growth hormone secretagogue receptor agonist and recombinant human insulin-like growth factor I. The treatment of somatotropin deficiency should be started as soon as the diagnosis confirmed. The FDA-approved somatropin for the treatment of somatotropin deficiency include Nutropin (Genentech), Humatrope (Lilly), Genotropin (Pfizer), Saizen (EMD Serono), Norditropin (Novo Nordisk), Tev-Tropin (Teva), and Omnitrope (Sandoz).

Somatotropin Deficiency Epidemiology

The epidemiology section covers insights about the historical and current Somatotropin Deficiency patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Somatotropin Deficiency Epidemiology Segmentation

  • Total Prevalent Cases of Somatotropin Deficiency

  • Gender-specific Prevalent Cases of Somatotropin Deficiency

  • Diagnosed and Treatable Cases of Somatotropin Deficiency

  • Onset-specific Prevalent Cases of Somatotropin Deficiency

Somatotropin Deficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Somatotropin Deficiency market or expected to get launched in the market during the study period. The analysis covers Somatotropin Deficiency market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Somatotropin Deficiency Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Somatotropin Deficiency market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Somatotropin Deficiency emerging therapies.

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years.

Somatotropin Deficiency Companies:

  • Pfizer

  • Genentech

  • Ascendis Pharma

  • OPKO Health

  • Lumos Pharma

  • Novo Nordisk

  • EMD Serono

And many others.

Somatotropin Deficiency Therapies covered in the report includes:

  • TransCon hGH

  • Somatrogon

  • LUM-201

And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Somatotropin Deficiency Competitive Intelligence Analysis

4. Somatotropin Deficiency Market Overview at a Glance

5. Somatotropin Deficiency Disease Background and Overview

6. Somatotropin Deficiency Patient Journey

7. Somatotropin Deficiency Epidemiology and Patient Population

8. Somatotropin Deficiency Treatment Algorithm, Current Treatment, and Medical Practices

9. Somatotropin Deficiency Unmet Needs

10. Key Endpoints of Somatotropin Deficiency Treatment

11. Somatotropin Deficiency Marketed Products

12. Somatotropin Deficiency Emerging Therapies

13. Somatotropin Deficiency Seven Major Market Analysis

14. Attribute Analysis

15. Somatotropin Deficiency Market Outlook (7 major markets)

16. Somatotropin Deficiency Access and Reimbursement Overview

17. KOL Views on the Somatotropin Deficiency Market.

18. Somatotropin Deficiency Market Drivers

19. Somatotropin Deficiency Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight
Somatotropin Deficiency Pipeline Insight
“Somatotropin Deficiency Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Somatotropin Deficiency Market.

Healthcare Blog By DelveInsight
Presbyopia Current and Future Treatment Options

3 in 4 Presbyopic cases use eyeglasses to correct their vision making eyeglasses occupying nearly half of the US Presbyopia treatment market. However, key companies such as Eyenovia, Orasis Pharmaceuticals, Allergan, Novartis, Ocuphire Pharma, Visus Therapeutics, are striving to change the picture through their novel pharmacotherapies. Learn more about, which therapy is going to nab the major chunk at Presbyopia Treatment Market and Key Companies

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States